How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

AI agents are not yet creative enough to carry out genuinely innovative open-ended AI research, it seems. The AI industry’s boldest promise right now is that AI will soon improve itself, with almost ...

Lucas Downey is the co-founder of MoneyFlows, and an Investopedia Academy instructor. Gordon Scott has been an active investor and technical analyst for 20+ years. He is a Chartered Market Technician ...

The Search Engine Land Awards celebrate individuals, agencies, and internal teams within the search marketing community who have demonstrated excellence in executing organic and paid search marketing ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Doretha Clemons, Ph.D., MBA, PMP, has been a corporate IT executive and professor for 34 years. She is an adjunct ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

View the basic RXRX option chain and compare options of Recursion Pharmaceuticals, Inc. on Yahoo Finance.